Teva, Medincell granted FDA review for long-acting antipsychotic
Source: SeekingAlpha
2026-02-21 09:09:02 ET
More on Teva Pharmaceutical, Royalty Pharma, etc.
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
- Royalty Pharma: 2025 Financial Performance And Strategic Outlook
- Corcept falls as appeals court sides with Teva in Korlym patent dispute
- Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Read the full article on Seeking Alpha
For further details see:
Teva, Medincell granted FDA review for long-acting antipsychotic
Royalty Pharma plc
NASDAQ: RPRX
RPRX Trading
0.64% G/L:
$46.48 Last:
906,242 Volume:
$45.94 Open:
RPRX Latest News
March 02, 2026 07:00:00 am
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
March 02, 2026 06:10:00 am
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026 06:01:00 am
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
RPRX Stock Data
$25,320,549,564
406,779,694
0.01%
217
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
